Discussion: African Americans are Disproportionately Affected by Vaccines
Check out this thought provoking discussion on how African Americans are disproportionately affected by vaccines leading to autoimmune conditions such as lupus and asthma. Panelists Curtis Cost, Sunayya Simon, Sister Battle and Frank Garry provide enlightening information on a little-investigated topic.
“Let’s Debate the Science!” RFK, Jr. on Whiskey Politics
RFK, Jr. joined Dave Sussman on the Whiskey Politics Show carried on America’s Voice News.
Mr. Sussman went to a recent event as a skeptic. What he heard made him question what he thought were the facts. Afterwards, he was so unsure, that he decided to take a deeper dive into the facts to expose the issue and understand why people questioning vaccines are not going away.
On the show, RFK, Jr. summarizes the critical issues surrounding the sickest generation of children and the need for vaccine safety. To the nay-sayers who dismiss with the label of “anti-vaccine” he says, “Let’s debate the science, no name calling!”
Caught on Camera: W.H.O Scientists Question Safety Of Vaccines
The bombshell video footage, published by Del Bigtree’s The Highwire, captures a series of statements—profoundly unsettling in their matter-of-factness—made by professionals who, in early December, attended the World Health Organization’s (WHO’s) two-day Global Vaccine Safety Summit on December 2 & 3 2019. Also read CHD’s accompanying article Look WHO’s Talking! Vaccine Scientists Confirm Major Safety Problems
00:19 Dr. Heidi Larson, MA PhD Anthropologist, Director of The Vaccine Confidence Project: There’s a lot of safety science that’s needed, and without the good science we can’t have good communication. So, although I’m talking about all these other contextual issues and communication issues, it absolutely needs the science as the backbone, you can’t repurpose the same old science to make it sound better if you don’t have the science that’s relevant to the new problem. So, we need much more investment in safety science.
00:52 Dr. Soumya Swaminathan, M.D., Chief Scientist, WHO, Pediatrician: I think we cannot over-emphasize the fact that we really don’t have very good safety monitoring systems in many countries, and this adds to the miscommunication and the misapprehensions, because we’re not able to give clear-cut answers when people ask questions about the deaths that have occurred due to a particular vaccine, and this always gets blown up in the media. One should be able to give a very factual account of what exactly has happened and what the cause of deaths are. But in most cases, there’s some obfuscation at that level, and therefore there’s less and less trust then in the system.
01:30 Dr. Martin Howell Friede, Coordinator, Initiative for Vaccine Research, WHO: Every time that there is an association, be it temporal or not temporal, the first accusation is it is the adjuvant, and yet without adjuvants we are not going to have the next generation of vaccines, and many of the vaccines that we do have, ranging from tetanus through to HPV, require adjuvants in order for them to work. So, the challenge that we have in front of us is how do we build confidence in this. And the confidence first of all comes from the regulatory agencies
02:00 Friede: When we add an adjuvant, it’s because it is essential. We do not add adjuvants to vaccines because we want to do so. But when we add them it adds to the complexity. And I give courses every year on how do you develop vaccines, how do you make vaccines. And the first lesson is while you’re making your vaccine if you can avoid using an adjuvant please do so. Lesson two is if you’re going to use an adjuvant use one that has a history of safety. And lesson three is if you’re not going to do that, think very carefully.
02:38 Dr. Stephen Evans, Professor of Pharmacoepidemiology: It seems to me that adjuvants multiply the immunogenicity of the antigens that they are added to, and that is their intention. It seems to me they multiply the reactogenicity in many instances, and therefore it seems to me that it is not unexpected if they multiply the incidence of adverse reactions that are associated with the antigen, but may not have been detected through lack of statistical power in the original studies.
03:17 Friede: You are correct. As we add adjuvants, especially some of the more recent adjuvants such as the AS01 saponin-derived adjuvants, we do see increased local reactogenicity. The primary concern though, usually, is systemic adverse events rather than local adverse events. And we tend to get, in the phase two and the phase three studies, quite good data on the local reactogenicity. Those of us in this room that are beyond the age of 50 who have had the pleasure of having the recent shingles vaccine will know that this does have quite significant local reactogenicity. If you got the vaccine, you know that you got the vaccine. But this is not the major health concern. The major health concern which we are seeing are accusations of long-term effects. So, to come back to this, I’m going to once again point to the regulators, it comes down to ensuring that we conduct the phase two and the phase three studies with adequate size and with appropriate measurement.
04:24 Dr. David Kaslow, M.D., V.P., Essential Medicines, Drug Development Program PATH Center for Vaccine Innovation and Access (CVIA): So in our clinical trials, we are actually using relatively small sample sizes, and when we do that, we’re at risk of tyranny of small numbers, which is you just need a single case of Wegener’s granulomatosis and your vaccine has to [04:39] ____. How do you prove a null hypothesis? And it takes years and years to try to figure that out. So it’s a real conundrum, getting the right size, dealing with the tyranny of small numbers, making sure that you can really do it, so I think one of the things that we really need to invest in are, kind of, better biomarkers, better mechanistic understanding of how these things work, so we can better understand adverse events as they come up.
05:12 Dr. Marion Gruber, Director, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, FDA: One of the additional issues that complicates safety evaluation is if you look at and you struggle with the length of followup that should be adequate in a… Let’s say a pre-licensure even post-marketing study, if that’s even possible. And again, as you mentioned pre-licensure clinical trials may not be powered enough. It’s also the subject population that you administer the adjuvant to, because we’ve seen data presented to us where an adjuvant, a particular adjuvant added to a vaccine antigen did really nothing when administered to a certain population, and it’s usually the elderly, compared to administering the same formulation to younger age strata. So, these are things which need to be considered as well and further complicate safety and effectiveness evaluation of adjuvants combined with vaccine antigens.
06:00 Dr. Bassey Okposen, Program Manager, National Emergency Routine Immunization Coordination Centre (NERICC), Abuja, Nigeria: I cast back my mind to our situation in Nigeria, where at 6 weeks, 10 weeks, 14 weeks, a child is being given different antigens from different companies and these vaccines have different adjuvant, different preservatives and so on. Something crosses my mind, is there a possibility of these adjuvants’ preservatives cross-reacting amongst themselves? Have there ever been a study on the possibility of cross-reactions from the panel members that you can share the experience with us?
06:44 Dr. Robert Chen, M.D., Scientific Director, Brighton Collaboration: Now, the only way to tease that out is if you have a large population database, like the Vaccine Safety Datalink as well as some of the other national databases that are coming into being, where the actual vaccine exposure is tracked down to that level of specificity of who is the manufacturer, what is the lab number, etcetera, etcetera, and there’s initiative to try to make the vaccine label information barcoded so that it includes that level of information so that in the future when we do these type of studies we’re able to tease that out. And in order to… Each time you subdivide then the sample size gets becoming more and more challenging. And that’s what I said earlier today about that we’re really only in the beginning of the era of large data sets where hopefully you could start to, kind of, harmonize the databases for multiple studies and there’s actually an initiative underway, Helen there may want to comment on it, to try to get more national vaccine safety database linked together, so we could start to answer these type of questions that you just raised.
08:05 Larson: The other thing that’s a trend and an issue is not just confidence in providers, but confidence of healthcare providers. We have a very wobbly health professional frontline that is starting to question vaccines and the safety of vaccines. When the frontline professionals are starting to question or they don’t feel like they have enough confidence about the safety to stand up to it, to the person asking them the questions. I mean, most medical school curriculums, even nursing curriculums, in medical school you’re lucky if you have a half day on vaccines, never mind keeping up-to-date with all this.[music]